%0 Journal Article
%A Godoy-Ortiz, Ana
%A Alba-Bernal, Alfonso
%A Pascual, Javier
%A Comino-Méndez, Iñaki
%A Alba, Emilio
%T Unveiling the Potential of Liquid Biopsy in HER2-Positive Breast Cancer Management.
%D 2022
%@ 2072-6694
%U http://hdl.handle.net/10668/20870
%X Invasive breast cancer (BC) is the most common cancer in women with a slightly increasing yearly incidence. BC immunohistochemical characterisation is a crucial tool to define the intrinsic nature of each tumour and personalise BC patients' clinical management. In this regard, the characterisation of human epidermal growth factor receptor 2 (HER2) status guides physicians to treat with therapies tailored to this membrane receptor. Standardly, a tumour solid biopsy is therefore required, which is an invasive procedure and has difficulties to provide the complete molecular picture of the tumour. To complement these standard-of-care approaches, liquid biopsy is a validated methodology to obtain circulating tumour components such as circulating tumour DNA (ctDNA) and circulating tumour cells (CTCs) from body fluids in an easy-to-perform minimal-invasive manner. However, its clinical validity in cancer is still to be demonstrated. This review focusses on the utilisation of both ctDNA and CTCs in early and metastatic HER2-positive BC tumours. We discuss recently published studies deciphering the capacity of liquid biopsy to determine the response to neoadjuvant and adjuvant therapies as well as to predict patients' outcomes.
%K HER2-positive breast cancer
%K circulating-tumour DNA
%K circulating-tumour cells
%K early breast cancer
%K liquid biopsy
%K metastatic breast cancer
%~